The medRxiv preprint title announces Sturgeon V2, described by the authors as a clinically applicable CNS tumor classifier trained on relabeled data. The work is available under doi: 10.64898/2026.10.19.26365910. The title frames this report as a second-generation model, and the phrase "trained on relabeled data" implies a deliberate revision of case labels before model training. The excerpt supplied for this rewrite contains the manuscript header, author list, and affiliations, but not the body text that would normally report methods, datasets, or results.
The author list spans multiple centers and specialties. Lead and corresponding names are affiliated with pediatric oncology, neuropathology, neurosurgery, and genomics institutes. Institutions named include the Princess Maxima Center for Pediatric Oncology, Erasmus MC Cancer Institute, Amsterdam University Medical Centers, Copenhagen University Hospital, the Oncode Institute and UMC Utrecht, the Institut für Medizinische Genetik und Pathologie in Basel, and U.S. centers such as the Mayo Clinic and the National Cancer Institute. This spread suggests multidisciplinary input across clinical and computational teams. The excerpt documents authorship and institutional ties; it does not, however, include specific roles, contribution statements, or funding sources in the visible text.
The medRxiv landing page for this manuscript explicitly states that the article is a preprint and has not been peer reviewed. The page carries the standard medRxiv advisory that the research should not yet be used to guide clinical practice. The authors and platform therefore present this work as preliminary. Any statement about clinical deployment, utility in diagnostic workflows, or patient-level outcomes would require peer review and confirmatory validation before adoption in practice.
From the excerpt provided, the only method-related detail conveyed by the authors is that the classifier is "trained on relabeled data." The specific processes used for relabeling—whether re-review by neuropathologists, consensus annotation, integration of molecular profiles, or automated relabeling techniques—are not described in the visible portion. Similarly, the excerpt does not list the classifier architecture, feature types (for example, methylation, sequence, histology image, or multi-omic inputs), nor the computational framework, loss functions, or hyperparameter strategy. Investigators reported a collaborative development effort, but the excerpt does not allow reconstruction of training set size, class distribution, or data provenance.
The supplied text does not include any numeric performance metrics, confusion matrices, cross-validation results, external validation cohorts, or head-to-head comparisons with prior classifiers. The excerpt is silent on sensitivity, specificity, area under the curve, calibration, or per-class accuracy. No details appear about clinical-case examples, adjudication of discordant cases, or prospective testing in routine diagnostic workflows. Because none of these elements are present in the provided material, they cannot be reported or summarized here.
Several practical and regulatory questions remain unanswered in the visible excerpt. The authors did not provide, within the supplied portion, a plan for clinical integration, such as laboratory validation, regulatory submissions, or prospective studies. The excerpt does not state whether the classifier will be released as open-source code, a packaged diagnostic, or a service. It also omits whether relabeling was retrospective or prospective and whether changes in labels materially altered case management recommendations.
Limitations and immediate next steps derive from the preprint status and the gaps in the provided text. The manuscript header and author list make clear that a new version of a CNS tumor classifier exists and that it was developed by a multi-institutional team; beyond that, the excerpt does not permit assessment of analytical validity, clinical validity, or clinical utility. Peer review, access to full methods and results, and transparent reporting of datasets and performance metrics are necessary before this tool could be evaluated for diagnostic use. The preprint itself may include those details, but they were not part of the excerpt presented for this rewrite. The most concrete, documentable facts here are the model name (Sturgeon V2), its intended application (CNS tumor classifier), the collaborative author list and affiliations, and the statement that the work remains unrefereed on medRxiv. The itemized technical and validation items above remain open questions pending access to the full manuscript and subsequent peer-reviewed publication.